RecruitingPhase 2NCT07356245

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma

Sponsor

Jonathan Brammer

Enrollment

44 participants

Start Date

Feb 12, 2026

Study Type

INTERVENTIONAL

Conditions

T-cell Lymphoma

Summary

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing ruxolitinib — a drug that modifies immune system signaling — as a maintenance treatment after a stem cell transplant for people with T-cell lymphoma who are in partial or complete remission. The goal is to prevent the cancer from coming back after transplant. **You may be eligible if:** - You are an adult with T-cell lymphoma (including PTCL, T-PLL, ATLL, or CTCL) who is in partial or complete remission between 35 and 120 days after your stem cell transplant - Your general health status is good (ECOG performance status 2 or less) - Your blood counts and organ function are within acceptable ranges - You are able to take oral medications - You are willing to use contraception throughout the study **You may NOT be eligible if:** - Your specific lymphoma subtype is ALK-positive or DUSP22-positive ALCL with a low-risk score in first complete remission - Your cancer is progressing, or you are receiving other systemic cancer treatments after the transplant (radiation is allowed) - You have previously had disease progression on ruxolitinib - You have active graft-versus-host disease (GVHD) requiring systemic treatment - You have active uncontrolled infections - You are pregnant or breastfeeding - You have had a heart attack or stroke within the past year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.